KANCHAN HLTHCARE
SpecialtyKANCHAN HLTHCARE is a specialty pharmaceutical company focused on Neurology, Respiratory, Dermatology.
KANCHAN HLTHCARE's Key Drugs
KANCHAN HLTHCARE's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
KANCHAN HLTHCARE's Recent FDA Approvals
New NDA/BLA approvals for KANCHAN HLTHCARE over the last two years — novel drugs only, excluding generics and label supplements.
KANCHAN HLTHCARE's Therapeutic Areas
KANCHAN HLTHCARE's approved drugs and pipeline span 3 therapeutic areas, led by Neurology and Respiratory. Weighted by commercial stage — approved drugs count most, then late-stage trials.
KANCHAN HLTHCARE's Top Competitors
KANCHAN HLTHCARE's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Eli Lilly, and Bayer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
KANCHAN HLTHCARE Pipeline Snapshot
Active clinical trials for KANCHAN HLTHCARE across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1967-11-06
- Latest
- 2024-06-05
- Applications
- 6